Granted Patent B2

US 12,559,458 · App. 18/116,891 · Granted Feb 24, 2026

Inventors: John Knight (Hereford, GB); Talbir Austin (Loughborough, GB)

Assignee: RESET PHARMACEUTICALS, INC.

C07D209/16A61P25/00C07B2200/13

Abstract

Claims (48)

1 . A co-crystal or salt consisting essentially of psilocin and a co-former, wherein the co-former is L-lactic acid, wherein the molar ratio of psilocin:L-lactic acid is about 1:1, and wherein the co-crystal or salt has an x-ray powder diffraction pattern comprising peaks at 13.4°, 16.8° and 19.5°±0.2° 2θ.

2 . The co-crystal or salt according to claim 1 , wherein the x-ray powder diffraction pattern further comprises peaks at 16.7°, 23.0° and 24.3°±0.2° 2θ.

3 . The co-crystal or salt according to claim 1 , wherein the x-ray powder diffraction pattern comprises seven or more peaks selected from 13.4°, 14.9°, 16.7°, 16.8°, 19.5°, 20.6°, 23.0°, 24.3° and 26.3°±0.2° 2θ.

4 . The co-crystal or salt according to claim 1 , wherein the x-ray powder diffraction pattern comprises the following peaks:

Angle [°2θ]

Rel. Int. [%]

11.0

30

13.4

96

14.2

14

14.9

47

16.7

55

16.8

89

19.5

100

20.1

10

20.3

22

20.6

38

22.2

17

22.5

11

22.8

18

23.0

52

24.3

77

24.4

33

26.3

39

29.1

16

34.0

10

5 . A kit comprising:

a co-crystal or salt as defined in claim 1 ; and

instructions for use of the co-crystal or salt in a method of treating a disease or condition selected from depression, anxiety and demoralization in a patient, the method comprising administering a therapeutically effective amount of the co-crystal or salt to the patient.

6 . A method of treating a disease or condition selected from depression, anxiety and demoralization in a patient, the method comprising administering a therapeutically effective amount of the co-crystal or salt as defined in claim 1 to the patient.

Assignments (2)

Continuity (7)

References Cited (400)